HER2 codon 655 polymorphism is associated with advanced uterine cervical carcinoma.
OBJECTIVE
It has been suggested that overexpression of HER2 in advanced cervical tumors can be considered an independent predictor of poor patient outcome.


METHODS
Employing PCR-RFLPs, we examined the distribution of HER2 Ile655Val (rs 1136201) genotypes and alleles in patients with advanced cervical cancer (n=109) and controls (n=220).


RESULTS
Odds ratio (OR) for patients with advanced cervical cancer with the HER2 Val/Val homozygous or Val/Ile heterozygous state was 1.778 (95% CI=1.117-2.830, p=0.0176). We also observed an association of the HER2 Val/Val genotype with advanced cervical cancer in the patient group OR=3.706 (95% CI=1.061-12.950, p=0.0459). However, we did not find a significant association between the distribution of genotypes or alleles and cancer characteristics for the HER2 Ile655Val polymorphism.


CONCLUSIONS
Our results indicate that the HER2 655Val variant may be associated with the incidence of advanced cervical cancer.
Kruszyna
Łukasz
Ł
Department of Biochemistry and Molecular Biology, Poznań University of Medical Sciences, 6 SwiecickiegoSt., 60-781 Poznań, Poland.
Lianeri
Margarita
M
Roszak
Andrzej
A
Jagodziński
Paweł P
PP
D000328:Adult; D000368:Aged; D019943:Amino Acid Substitution; D002277:Carcinoma / Q000453:epidemiology / Q000235:genetics*; D016022:Case-Control Studies; D003062:Codon / Q000235:genetics; D005260:Female; D005787:Gene Frequency; D008040:Genetic Linkage; D005820:Genetic Testing; D005838:Genotype; D006801:Humans; D015994:Incidence; D007532:Isoleucine / Q000235:genetics; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000502:physiology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000235:genetics*; D014633:Valine / Q000235:genetics
D003062:Codon; D007532:Isoleucine; D018719:Erb-b2 Receptor Tyrosine Kinases; D014633:Valine; C508053:ERBB2 protein, human